Extracorporeal membrane oxygenation (ECMO) is frequently associated with bleeding and coagulopathy complications, which may lead to the need for transfusion of multiple blood products. However, blood transfusions are known to increase morbidity and mortality, as well as hospital cost, in critically ill patients. In current practice, patients on ECMO receive a transfusion, on average, of 1-5 packed red blood cells (RBCs)/day, with platelet transfusion accounting for the largest portion of transfusion volume. Generally, adult patients require more transfusions than neonates or children, and patients receiving venovenous ECMO for respiratory failure tend to need smaller transfusion volumes compared to those receiving venoarterial ECMO for cardiac failure. Observation studies have reported that a higher transfusion volume was associated with increased mortality. To date, the evidence for transfusion in patients undergoing ECMO is limited; most knowledge on transfusion strategies was extrapolated from studies in critically ill patients. However, current data support a restrictive blood transfusion strategy for ECMO patients, and a low transfusion trigger seems to be safe and reasonable.
Introduction
Extracorporeal membrane oxygenation (ECMO) is now increasingly used around the world [1] . However, the management of hemoglobin levels and transfusion of blood products in patients receiving ECMO is still a subject of debate.
Although the Extracorporeal Life Support Organization (ELSO) recommends maintaining hemoglobin levels within the normal range (12-14 g/dL) during ECMO [1] , these guidelines are not evidence-based. In addition, modern ECMO systems are more biocompatible, and associated with less hemolysis and fewer bleeding complications, compared to those in the early ECMO era, further reducing the need for transfusion.
Blood transfusions are well known to be associated with adverse effects, such as infections and immune-mediated reactions (Table 1) [2, 3] . As randomized controlled trials have shown benefit of reducing transfusions [4, 5] , current guidelines on red blood cell (RBC) transfusion advise a restrictive strategy in critically ill patients. Accordingly, patients on ECMO may also benefit from the restrictive strategy that does not require maintaining hemoglobin levels cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. [TRISS] trial) and reported that patients who were transfused at a hemoglobin threshold of 7 g/dL, as compared to those transfused at a hemoglobin threshold of 9 g/dL, received fewer transfusions and had similar rates of 90-day mortality and ischemic events [5] . Although some authors recently reported data against restrictive transfusion strategies [14] , a meta-analysis by Holst et al. [15] showed that restrictive transfusion strategies were associated with a reduction in the number of RBCs transfused and percent of patients transfused, without increasing mortality or ischemic events. Therefore, taken together, restrictive transfusion strategies are more likely to be beneficial than liberal strategies in critically ill patients, and at present, a low hemoglobin target (i.e., 7 g/dL) is recommended to be used for transfusion threshold.
Blood Transfusions When Old ECMO Systems Were Used
Older ECMO systems used a roller pump and a long and non-biocompatible (non-heparin-coated) circuit [16] .
The system required a priming volume of more than 2 liters and frequent ECMO circuit changes [17] . These factors increased activation of the coagulation system and bleeding complications [18] , and were associated with high transfusion volumes. In particular, adult patients on ECMO, compared to neonates or children, required a higher volume of transfusions and therefore, it imposed a considerable burden on hospital blood banks [19, 20] .
In a study by Butch et al. [19] , the daily transfusion units of packed RBCs, PCs, and fresh frozen plasma for ECMO patients were 3.2, 13.6, and 0.1 units, respectively. The study found that about 80% of transfusion volumes were given during ECMO treatment, and
PCs accounted for the largest portion of transfusions.
Tolksdorf et al. [17] also reported that packed RBCs of 6.8 units were transfused within the first 24 hours after ECMO system changes in the absence of an autotransfusion device. In the early period of ECMO use, the ECMO system was primed with blood, and the target ranges for hemoglobin (> 14 g/dL) and anticoagulation levels (activated clotting time [ACT], 180-220 seconds) were high [19, 21, 22] . Hence, the transfusion requirement was substantial. However, in present-day practice, crystalloids (< 1 liter) are used for priming, and the use of heparincoated biocompatible circuits, small-sized oxygenators, and short-length circuits decrease bleeding complications and the need for transfusion.
Current Transfusion Practice in ECMO Patients
Transfusion requirements are greater among adult patients receiving ECMO than neonates or children receiving ECMO because of the larger size and longer duration of ECMO among adults [23] . Currently, the ELSO guidelines recommend maintaining hemoglobin levels between 12 and 14 g/dL, and platelet counts at > 75,000/mm 3 [1] . (63/68). In a study by the Italian ECMO network on patients with influenza ARDS, the average volume of RBCs transfused was 1,500 mL (400-2,990 mL) per patient (i.e., 0.6 units/day) during the 10 ECMO days [28] .
Evidence for Less Transfusion in ECMO Patients
Smith et al. [29] reported that among 484 infants or children (cardiac ECMO 40%, non-cardiac ECMO 42%, and extracorporeal cardiopulmonary resuscitation [ECPR], 18%), transfusion volume was the largest among patients undergoing cardiac ECMO, followed by those on ECPR; nonsurvivors received more transfusions than survivors. Also, in a study by Omar et al. [26] , the transfusion volume (RBCs and platelets) was higher in non-survivors compared to survivors.
Recently, two retrospective observational studies were published on restrictive transfusion strategies [30, 31] . In a German study of 18 patients with severe ARDS [31] , hemoglobin concentrations were maintained between 7.0 and 9.0 g/dL, and the transfusion trigger was a hemoglobin level < 7.0 g/dL. Their results showed that the mean hemoglobin level and hematocrit were 8.3 g/dL and 25.0% during ECMO, which were lower than the levels found in influenza ARDS patients by the Italian ECMO network [28] . They found that overall mortality was 38.9%, but transfusion volume tended to be higher in lower than previously reported rates. They also noted that rates of thrombosis and bleeding complications were not remarkable, and that number of transfusions, rather than baseline hemoglobin levels, were associated with higher mortality [30] .
Regarding fluid management, we are aware of a study that compares two-fluid management strategies in pa-tients with acute lung injury, published in 2006 by the ARDS Clinical Trial Network [32] . The study provided strong evidence for the beneficial effects of conservative fluid management on patients with lung injury. This is relevant to patients undergoing ECMO, for whom blood transfusions are considered. ELSO guidelines also recommend that diuretics be used until dry weight is achieved. However, it is worth considering that the transfusion (or fluid) strategy in patients undergoing ECMO for respiratory failure could be different from those undergoing ECMO for cardiac failure [33] .
Other Strategies for Reducing Transfusion Volume
RBC transfusions during ECMO system change (~2.5 liters) can induce acute volume overload, activate the coagulation system, and cause an inflammatory reaction. Tolksdorf et al. [17] performed autotransfusion in 7 patients on ECMO, and it reduced RBC transfusion volume from 6.8 to 1.9 units. The advantages of autologous transfusion are a lower humoral immune response, lower infection risk, and shorter length of hospital stay. In particular, the authors found that the depletion of leukocytes and platelets using cell saver, in contrast to whole blood out of heart-lung machines in cardiac surgery, can reduce inflammatory response and improve lung function after transfusion. Also, in a study by Agerstrand et al. [30] , autotransfusion during decannulation was included in their blood conservation protocol.
The duration of ECMO was associated with volume of transfusion and a tendency towards decreased platelet count. Hence, it is recommended to attempt to shorten the duration of ECMO [23, 34] . Furthermore, minimizing daily samplings could be regarded as a strategy for fewer blood transfusions [30, 34] , and some authors have emphasized the importance of standardized transfusion protocol and education of medical personnel [30, 34] .
Although feasible in clinical practice, they need to be further investigated in the future.
Conclusions
To date, most knowledge on transfusion strategies was extrapolated from studies in critically ill patients; evi- 
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